(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia

• Status: Not yet recruiting
• Trial end date: 2024-06-30
• Target enrollment: 0
• Participant gender: Male

Summary

To compare between efficacy of phosphodiesterase5 inhibitors (tadalafil 5 mg) and Alpha Blockers (tamsulosin 0.4 mg) monotherapy vs combined therapy in treatment of lower urinary tract symptoms of benign prostatic hyperplasia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Adrenergic alpha-Antagonists; Phosphodiesterase 5 Inhibitors; Tadalafil

Criteria

Inclusion Criteria:

1 - Men > 45 years with LUTS/BPH for > 6 months 2- IPSS of ≥ 8 and Qmax of ≥ 4 to≤ 15 mL/s

Exclusion Criteria:

1. PSA level of > 10.0 ng/mL (if ≥ 4.0 to≤ 10.0 ng/mL prostate cancer will be excluded).

2. Post-voidresidual urine volume of ≥ 150 mL.

3. Previous Urine Retention or Urethral Catheterization .

4. other pathology such as urinary bladder stone , bladder mass or neurogenic bladder .

5. Any case of LUTS other than BPH (urinary bladder stone, neurogenic bladder, bladder neck contracture,rethral stricture, bladder cancer, acute or chronic prostatitis, acute or chronic urinary tract infection).

6. patients supposed to undergo intraocular operation (as cataract operation) .

7. History of head injury or cerebrovascular stroke or spinal injury.

8. pelvic fracture.

9. Uncontrolled diabetic patient.

10. Patients with chronic obstructive lung disease on medical treatment.

11. Parasympatholytic drugs are contraindicated during the study. 12. Patients refusing to share in the study.